Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:2017:4537532.
doi: 10.1155/2017/4537532. Epub 2017 Jun 15.

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site

Jonathan D Marotti  1   2 , Kristen E Muller  1 , Laura J Tafe  1   2 , Eugene Demidenko  3 , Todd W Miller  2   4
Affiliations

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site

Jonathan D Marotti et al. Int J Breast Cancer. 2017.

Abstract

Background: Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) has been implicated in cancer growth, metastasis, and response to phosphatidylinositol 3-kinase (PI3K) inhibitor therapy. The aim of this study was to determine whether P-Rex1 expression differs between primary and metastatic human breast tumors and between breast cancer subtypes.

Design: P-Rex1 expression was measured in 133 specimens by immunohistochemistry: 40 and 42 primary breast tumors from patients who did versus did not develop metastasis, respectively, and 51 breast-derived tumors from metastatic sites (36 of which had matching primary tumors available for analysis).

Results: Primary breast tumors showed significant differences in P-Rex1 expression based on receptor subtype. ER+ and HER2+ primary tumors showed higher P-Rex1 expression than primary triple-negative tumors. HER2+ metastases from all sites showed significantly higher P-Rex1 expression compared to other metastatic receptor subtypes. Solid organ (i.e., brain, lung, and liver) metastases showed higher P-Rex1 expression compared to bone metastases.

Conclusions: P-Rex1 expression is increased in ER+ and HER2+ breast cancers compared to triple-negative tumors. P-Rex1 may be differentially expressed in metastatic tumors based on site and receptor status. The role of P-Rex1 in the development of breast cancer metastases and as a predictive biomarker of therapeutic response warrants further investigation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
P-Rex1 expression in primary breast tumors. P-Rex1 is highly expressed in luminal (Lum) compared to triple-negative (TN) breast cancers. Each point represents mean P-Rex1 histoscore from two pathologists. Horizontal bars indicate mean histoscore for each receptor subtype. Data were analyzed by ANOVA followed by Tukey's HSD post hoc testing between groups.
Figure 2
Figure 2
P-Rex1 immunohistochemical expression in primary breast cancers and metastatic sites. (a) Primary ER+ tumor with high expression. (b) Primary HER2+ tumor with high expression. (c) Primary triple-negative tumor with no detectable expression in malignant cells. (d) HER2+ lung metastasis with high expression. (e) ER+/HER2− brain metastasis with high expression. (f) ER+/HER2− bone metastasis with no detectable expression in malignant cells. All images were obtained at 200x magnification.
Figure 3
Figure 3
P-Rex1 expression in metastatic breast cancers. P-Rex1 expression is lower in bone metastases compared to brain, lung, and liver metastases. Each point represents mean P-Rex1 histoscore from two pathologists. Horizontal bars indicate mean histoscore for each receptor subtype within each metastatic site.
Figure 4
Figure 4
P-Rex1 expression in matched primary breast tumors and metastases. Each point represents mean P-Rex1 histoscore from two pathologists. Lines indicate matching pairs and metastatic tumors.
See this image and copyright information in PMC

References

    1. Blows F. M., Driver K. E., Schmidt M. K., et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Medicine. 2010;7(5) doi: 10.1371/journal.pmed.1000279. - DOI - PMC - PubMed
    1. Tang P., Tse G. M. Immunohistochemical surrogates for molecular classification of breast carcinoma: A 2015 update. Archives of Pathology and Laboratory Medicine. 2016;140(8):806–814. doi: 10.5858/arpa.2015-0133-RA. - DOI - PubMed
    1. American_Cancer_Society. Cancer Facts and Figures 2016. Atlanta: American Cancer Society, 2016.
    1. Savci-Heijink C. D., Halfwerk H., Hooijer G. K. J., Horlings H. M., Wesseling J., van de Vijver M. J. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Research and Treatment. 2015;150(3):547–557. doi: 10.1007/s10549-015-3352-0. - DOI - PMC - PubMed
    1. Dillon L. M., Bean J. R., Yang W., et al. P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 2015;34(30):3968–3976. doi: 10.1038/onc.2014.328. - DOI - PMC - PubMed

LinkOut - more resources